Ticker LaunchIPO · BCAB
BioAtla, Inc.
BioAtla, Inc. (BCAB) priced its initial public offering on Dec 17, 2020 at $18.00 per share, above its $15.00–$17.00 range, raising $189M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $577.6M. J.P. Morgan was lead-left underwriter, joined by Jefferies, Credit Suisse and BTIG. Dechert and Cravath advised the underwriters.
- Status
- IPO
- Ticker
- BCAB
- Exchange
- Nasdaq Global Market
- Priced
- Dec 17, 2020
- IPO price
- $18.00
- Price range
- $15.00–$17.00
- Raised
- $189M
- Market cap at IPO price
- $577.6M
- First filed
- Nov 13, 2020
- Underwriters
- J.P. Morgan, Jefferies, Credit Suisse and BTIG
- Sector
- Biotech & pharma
- Country / state
- CA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Nov 13, 2020
- Latest amendment Dec 9, 2020
- Final prospectus (424B4) Dec 17, 2020
- All filings on EDGAR CIK 1826892
Other Biotech & pharma IPOs in 2020
- Dogwood Therapeutics, Inc.VIRI · Dec 18, 2020 · $30M
- 4D Molecular Therapeutics, Inc.FDMT · Dec 14, 2020 · $193.2M
- AbCellera Biologics Inc.ABCL · Dec 14, 2020 · $483M
- Nanobiotix S.A.NANO · Dec 11, 2020 · $98.5M
- Sigilon Therapeutics, Inc.SGTX · Dec 7, 2020 · $126M
- ARS Pharmaceuticals, Inc.SBTX · Dec 4, 2020 · $241.5M